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Radiological assessment of 
effectiveness of soluble RAGE in 
attenuating Angiotensin II-induced 
LVH mouse model using in vivo 9.4T 
MRI
Dan Heo1, soyeon Lim2, Jiye Lee3, Myung Eun Lee3, Soyoung Cho3,4, Jisu Jeong3,4, Miran seo3, 
Sungha park3,5,6,7 & Jaemoon Yang1,8
We investigated the effectiveness of soluble Receptor for Advanced Glycation Endproducts (sRAGE) 
in attenuating angiotensin II (AngII)-induced left ventricular hypertrophy (LVH) using in vivo 9.4T 
cine-magnetic resonance imaging (CINE-MRI). Mice were divided into four groups: AngII (n = 9), saline 
(n = 10), sRAGE (n = 10), and AngII + sRAGE (n = 10). CINE-MRI was performed in each group after 
administration of the AngII or sRAGE, and CINE-MR images were analyzed to obtain parameters 
indicating cardiac anatomical and functional changes including end-diastolic and end-systolic blood 
volume, end-diastolic and end-systolic myocardial volume, ejection fraction, end-diastolic and 
end-systolic myocardial mass, and LV wall thickness. LVH observed in AngII group was significantly 
attenuated by sRAGE. These trends were also observed in histological analysis, demonstrating that 
cardiac function tracking using in vivo and real-time 9.4T MR imaging provides valuable information 
about the cardiac remodeling induced by AngII and sRAGE in an AngII-induced LV hypertrophy mice 
model.
Left ventricular hypertrophy (LV hypertrophy, LVH) is an important marker of organ damage in hypertension 
and also an independent risk factor for sudden death1, ventricular arrhythmias2, myocardial ischemia3, cardio-
vascular disease (CVD)4, and congestive heart failure5. Studies have shown that renin-angiotensin system (RAS), 
especially angiotensin II (AngII), exhibits important effects on development of cardiac hypertrophy and reg-
ulation of LV function6. Direct cardiac actions of AngII include stimulation of cardiac contractility; accelera-
tion of protein synthesis, which results in cardiac hypertrophy; and activation of a membrane phospholipase7. 
Activation of RAS signaling is also intimately related with the expression level of receptor for advanced glycation 
endproducts (receptor for AGE, RAGE), which belongs to the immunoglobulin superfamily of cell surface mole-
cules8,9. RAGE is a pattern-recognizing receptor that engages with other non-glycated peptides which commonly 
have multiple β-sheets, including high-mobility group box 1 protein (HMGB1)10, S100/calgranulin11, amyloid 
fibrils12, and Mac-113. Since most of these ligands are common factors that are known to induce severe inflam-
matory diseases and as these factors can also activate RAGE-signaling pathway, RAGE has been purported to 
be a potential therapeutic target in various inflammatory diseases14–16. In our previous study, we demonstrated 
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that RAGE has a pivotal regulatory role in AngII-induced cardiomyocyte hypertrophy through PKCs-EKR1/2 
and NFκB-NLRP3-IL1β-signaling pathways in vitro, and demonstrated that soluble RAGE (sRAGE) as a decoy 
receptor for RAGE can attenuate AngII-induced cardiomyocyte hypertrophy in vitro17. However, the protective 
role of sRAGE in animal models of LVH has not been investigated.
In this study, we used 9.4T pre-clinical magnetic resonance imaging (MR imaging, MRI) instrument to obtain 
cardiac cinematic-MR (CINE-MR) images with high temporal and spatial resolution in live AngII-induced LV 
hypertrophy mouse models. CINE-MR imaging is very useful for the assessment of CVD, as it has high soft tissue 
contrast and spatial resolution and can also allow observation of biological functions, such as blood flow velocity 
and ratio, at live objectives18,19. However, since it is difficult to visualize the fast heartbeat of mice (300 beats/min) 
using MRI under 3.0T magnetic field, we used ultra-high field MRI to secure enough spatial and temporal resolu-
tion. The aim of this study was 1) to verify the cardiac functional and anatomical changes of AngII-induced LVH 
mouse model and 2) to determine the efficacy of treatment of sRAGE on attenuating AngII-induced LVH using 
CINE-MRI. For quantitative analysis, we obtained six parameters related to LV blood volume, as well as muscle 
volume and weight, from CINE-MR images. After in vivo MRI measurements, blood pressure, heart weight, and 
myocyte cross-sectional area (CSA) of cardiac specimen was obtained to confirm the findings on MRI.
Materials and Methods
LVH animal model. All procedures in this study were approved by the Institutional Animal Care and Use 
Committee of Yonsei University (approval reference number: 2014-0059) and were performed in accordance with 
the guidelines and regulation of the Association for Assessment and Accreditation of Laboratory Animal Care 
International. Male C57BL/6J mice at 8 weeks of age were purchased from the Jackson Laboratory (Bar Harbor, 
ME, USA) and used in this study. CINE-MRI was carried out before and after drug infusion in each group; saline 
(n = 10), AngII (n = 9), sRAGE (n = 10), and AngII + sRAGE (n = 10). To induce LVH, mice were anaesthetized 
by isoflurane (0.5%~1.0%/kg) and AngII (Sigma, St. Louis, USA) was infused into the mice subcutaneously at 
a concentration of 1.5 μg/min/kg for 4 weeks using osmotic mini-pumps (Alzet, model 2004, Cupertino, CA). 
sRAGE (Y-biologics, Daejon city, Korea, 2 μg/mouse) treatment was performed by daily intraperitoneal injection 
for 4 weeks. After CINE-MRI, mouse tail-cuff systemic blood pressure (BP) was measured on unanesthetized 
mice 4 weeks after infusion using BP-2000 Blood Pressure Analysis System (Visitech Systems, North Carolina, 
USA) according to the manufacturer’s instruction. After sacrifice, histological analysis for the extracted hearts 
was also performed, and body weight and tibia length were measured.
In vivo MR imaging of LVH animal model. In vivo cardiac CINE-MR imaging was conducted on a 9.4T 
animal MRI (BioSpec 94/20 USR, Bruker, Ettlingen, Germany) to confirm the difference of cardiac function 
among drug treatment groups (Fig. 1). It was acquired using a cylindrical volume RF coil (40 mm bore size) in 
C57BL/6 mice (n = 39) at 8 weeks of age before the implantation of osmotic pump. Anesthesia was induced by 
3.0% isoflurane in oxygen and maintained using 1.0 ~ 2.0% isoflurane during MR imaging. Electrocardiogram 
and respiratory data were monitored during the scan. CINE-MR imaging was based on bright blood fast low 
angle shot (FLASH) CINE imaging: TR = 6 msec, TE = 2.1 msec, number of averages = 6, FOV = 32 × 32 mm2, 
acquisition matrix = 256 × 256, spatial resolution = 125 × 125 × 1,000 μm3, acquisition time = 270 sec, images in 
an acquisition = 35. To obtain the entire LV images of the heart, coronal view imaging of heart displaying car-
diac apex and aortic arch was performed. Subsequently, CIEN-MR images were acquired in 1-mm thickness by 
short-axis slice, which was orthogonally oriented with the line joining from the end of cardiac apex and aortic 
arch, and we called this “short-axis slice”. After infusion of the drugs for 4 weeks, in vivo cardiac CINE-MRI was 
conducted again using the same method.
Analysis of MR images. MR images were analyzed by ParaVision 5.1 software (Bruker, Germany). Cardiac 
function of LVH mice model was assessed by measuring of the left ventricle volume at ED and ES. In detail, the 
region of interest was drawn on LV, its area (ALV) was measured, and bright blood area of LV was separated by sig-
nal intensity. LV blood volume, myocardial volume and weight at the end of diastole (EDbv, EDmv, and EDmw), 
or end of systole (ESbv), were determined by the following formulas:
Figure 1. Schematics demonstrate the experimental process for the cardiac function tracking of angiotensin II-
induced LVH models using in situ and 9.4T MRI.
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Ab is bright blood area of LV which is displayed as largest or smallest area from the acquired CINE-MR images, 
t is slice thickness, n is the number of short-axis slices, and ρ is myocardial density, assumed as 1.05 g/mL20. 
Ejection-fraction (EF) of heart was determined by:
=
−
×EF(%) EDbv ESbv
EDbv
100
The mean wall thickness of LV was calculated by ten lines that were drawn on LV wall of short-axis slice at ED.
Histological analysis. After the in vivo MRI, all mice were sacrificed by perfusion after anesthesia, and 
their hearts were extracted. The hearts were weighted, fixed by 10% formalin solution over 24 h, and then cut 
transversely to generate paraffin block. For histological staining, 5-µm section was generated. After dewaxing 
and rehydration, wheat germ agglutinin (WGA) staining was conducted to analyze cardiomyocyte CSA using 
WGA-Alexa Fluor 594 (ThermoFisher Scientific, MA, USA)21. The stained tissue slides were randomly imaged 
at LV area of heart using fluorescence Microscope (Olympus, BX53, Tokyo, Japan), and estimated using Image J.
Statistical analysis. All measured data were represented as mean and standard deviation from independent 
measurements. Statistical analyses were performed using Student’s t-test for verification of the changes contingent 
on drug administration in each group, and analysis of variance (ANOVA) with Bonferroni correction for compar-
ison between experimental groups. The results were considered statistically significant when p < 0.05.
Results
Figure 2 shows cardiac images of representative mouse in each group at the end of drug infusion. All images were 
obtained with bright blood FLASH CINE-MR images at ED or ES. The number of short-axis slices was not signif-
icantly different among experimental groups after infusion of drugs. The maximum difference of short-axis slice 
number was found in less than one slice. For a more precise analysis of MR images, six anatomical and functional 
parameters were selected as the principal variables indicating changes in cardiac function and morphology before 
and after implantation of osmotic drug infusion pump (Table 1). These parameters were as follows: EDbv, ESbv, 
EDmv, EDmw EF, and LV wall thickness (LVWT). Comparison of changes in these parameters between each 
treatment group after drug infusion are shown as box plots in Fig. 3. First, when parameters were determined 
before the implantation of drug pump, there was no statistically significant difference among groups (Fig. 3, white 
bars). All groups had healthy cardiac conditions, and also showed normal EF within the range of between 65% to 
73%. The six parameters after drug infusion (gray bar) were compared to baseline (white bar) for each group. In 
both of AngII group and AngII + sRAGE group, statistically significant differences were found post-infusion for 
all parameters (p < 0.01) except EF. In contrast, saline group and sRAGE group showed same statistical trends in 
EDmw, EDmv, LVWT, and EF.
Next, we compared the six parameters after drug infusion between four experimental groups (Fig. 3, gray 
bars). AngII group showed significant increase in EDbv, ESbv, EDmv, and EDmw compared to saline group, 
demonstrating consistent induction of LVH. However, there was no significant difference in LVWT. For the 
assessment of inhibition effectiveness of sRAGE on AngII-induced LVH, we compared the six parameters after 
drug infusion between AngII and AngII + sRAGE groups. The results showed that EDmw was significantly lower 
in AngII + sRAGE group compared to AngII group (p < 0.05, Fig. 3d).
When we compared delta values of the six parameters between each group by administration of AngII or 
sRAGE, the inhibitory effect of sRAGE on AngII-induced LVH was more obviously observed (Fig. 4). The results 
showed that AngII + sRAGE group had a significantly smaller increase in ΔEDmv and ΔEDmw compared to 
AngII group (Fig. 4c,d), while there was no significant difference for the changes in ΔLVWT. In contrast, no 
significant difference was observed between saline group and sRAGE group, suggesting that sRAGE did not have 
any anti-hypertrophy effect without concomitant stimulation with AngII.
For confirmation of the above-mentioned results, blood pressure was also measured in all groups (Fig. 5a,b). 
There was significant increase in blood pressure in AngII group compared to saline and sRAGE groups, demon-
strating the effectiveness of AngII osmotic pump infusion in elevating blood pressure. There was no significant 
difference in BP between AngII and AngII + sRAGE groups, demonstrating that the efficacy of sRAGE in attenu-
ating LVH was BP independent. To verify the anatomical changes within the heart, all mice were sacrificed at the 
end of their second MRI examination.
The heart was extracted and weighed to determine the weight of the heart alone, and when controlled for body 
weight (Fig. 5c,d). LVH induced by AngII was evident through gross visualization of the whole heart (Fig. 5c). 
The heart weight/body weight in AngII group was significantly higher compared to that in AngII + sRAGE 
group (p < 0.05, Fig. 5d). WGA staining was conducted to analyze cardiomyocyte cross-sectional area (Fig. 5e). 
WGA-stained images were displayed to compare the size of cardiomyocytes between each group. Cardiomyocyte 
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cross-sectional area was determined by estimating the area of myocytes in the region of interest, and normal-
ized saline group was 100%. Cross-sectional area was greater in AngII group than in saline group mice (over 
150%, p < 0.0001). Also, AngII group showed significantly greater mean CSA compared to AngII + sRAGE group 
(p < 0.0001), confirming the findings demonstrated by cardiac MRI. Expression levels of hypertrophic markers 
were also examined using heart tissues to support histological analysis (Fig. S1, see supporting information). 
β-MHC, ANP, and NFATc1 expression levels tended to increase with AngII-infused hearts, and sRAGE treatment 
tended to attenuate their expression levels.
To verify the correlation between CINE-MRI and histological data, linear regression analysis was conducted 
with n ≥ 4 samples from each group (Fig. 6). There was a good correlation between EDmw and HW (R = 0.79, 
R2 = 0.63, and p < 0.0001), with all data points being in the 95% prediction band (Fig. 6a). There was a good cor-
relation between EDmv and CSA (R = 0.73, R2 = 0.54, and p = 0.0002) as well.
Figure 2. MR images displaying the heart of each experimental group at ED or ES after drug infusion by 
osmatic drug pump.
AngII/
sRAGE
EDbv ESbv EDmv EDmw LVWT EF
(mm3) (mm3) (mm3) (mg) (μm) (%)
Pre
−/− 44.0 ± 3.9 11.9 ± 1.7 77.1 ± 8.6 81.0 ± 9.0 656.4 ± 49.9 73.0 ± 2.6
+/− 45.7 ± 4.1 13.4 ± 3.4 73.2 ± 3.8 76.9 ± 4.0 660.0 ± 35.0 71.5 ± 6.4
−/+ 50.7 ± 4.2 17.5 ± 4.6 76.8 ± 5.2 80.6 ± 5.5 632.2 ± 45.5 65.6 ± 7.8
+/+ 48.6 ± 4.4 16.5 ± 4.5 78.1 ± 7.4 82.0 ± 7.8 642.2 ± 27.4 67.4 ± 6.3
Post
−/− 46.6 ± 5.4 11.5 ± 2.0 88.6 ± 6.6 93.0 ± 7.0 818.4 ± 60.5 75.4 ± 2.4
+/− 69.9 ± 19.5 26.3 ± 18.2 112.3 ± 17.7 118.0 ± 18.6 813.5 ± 66.2 68.3 ± 2.4
−/+ 51.0 ± 2.7 13.7 ± 3.9 86.8 ± 7.1 91.1 ± 7.5 769.7 ± 74.3 73.2 ± 7.2
+/+ 66.4 ± 9.5 23.4 ± 5.2 100.8 ± 10.5 105.8 ± 11.0 796.8 ± 53.0 65.4 ± 3.5
Table 1. The factors were selected as indicators of cardiac function in this study.
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Discussion
In the present study, we successfully detected AngII-induced functional and anatomical changes of hearts using 
in vivo real-time MR imaging method, and the acquired data indicated that sRAGE was effective in attenuat-
ing AngII-induced LVH. Previous studies have demonstrated AngII as an important mediator in the devel-
opment of cardiac hypertrophy22–24, interstitial cardiac fibrosis25,26, and LV dysfunction27–29. Components of 
renin-angiotensin system, including AngII, constitute an autocrine/paracrine cardiac tissue renin-angiotensin 
system30–33. AngII receptors have been characterized in cardiomyocytes, cardiac fibroblasts25,26,34, and coronary 
arteries26,35. Although both angiotensin type 1 and 2 receptors (AT1R and AT2R) are present in cardiac and cor-
onary tissue, many of the adverse effects of AngII on growth, myocardial fibrosis, and LV dysfunction are medi-
ated through AT1R24,34–37. Accumulating evidence suggest that many of the adverse cardiac effects of AngII are 
triggered by reactive oxygen species (ROS), partially generated by an NADPH oxidase-dependent pathway38–42. 
These results can help with our understanding of the pathogenesis and biomolecular interactions involved in 
AngII and LVH.
In these previous studies of CVD using animal models, differences between experimental groups were con-
firmed by invasive and indirect methods such as blood examination or end-point assays, like tissue staining and 
western blotting17,24,37,41,43,44. The major disadvantage of these methods is that the results from one assay are lim-
ited and discontinuous. This impedes the study of biological or phenotypical changes during disease progression, 
since continuous observation is impossible in a living model.
To circumvent this problem using end-point assays, much effort has been exerted in developing non-invasive 
techniques such as MRI, computed tomography, ultrasound (US) imaging, and positron emission tomography. 
Among these, MRI is particularly useful for assessing CVD as it has high soft tissue contrast and spatial res-
olution, and can also allow observations of biological functions such as blood flow velocity and ratio18,19,45,46. 
Although echocardiogram is the most widely used imaging technique for experiments in small animal cardi-
ovascular disease models, MRI is more suitable for monitoring of cardiac remodeling between baseline and 
post-intervention, due to its higher spatial resolution that allows better soft tissue contrast. Recently, US has also 
had significant improvement in spatial resolution, which enabled improved visualization of organs or tissues 
due to improvement of transducers and image-processing techniques47,48. Moreover, US can perform real-time 
imaging, allowing radiologist to observe lesions quickly and easily. However, since most US instruments adopt 
hand-held transducers, it is difficult to obtain accurate cross-sectional images in rapidly beating heart. Therefore, 
MRI is more suitable for follow-up studies that require a certain deep and cross-sectional image of heart for 
Figure 3. Graphs displaying the cardiac function and anatomy-indicating factors measuring from the cardiac 
CINE-MRI (a) EDbv, (b) ESbv, (c) EDmv, (d) EDmw, (e) EF of LV, (f) LVWT. −/−: saline group, +/−: AngII 
group, −/+: sRAGE group, +/+, AngII + sRAGE group. Straight line: median value, dashed line: mean value, 
*p < 0.05, **p < 0.01.
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meta-image post-processing. Conventionally, LV volumetric analysis using US had applied a formula that was an 
estimation method from LV diameter at the parasternal short axis49,50. In our MRI study, about 300 heart image 
slices were analyzed from 39 mice, and we calculated the cardiac functional parameters by a method that was dif-
ferent from the conventional calculation method using one-slice image to get more accurate data. From this study, 
we found a good correlation between non-invasively obtained EDmw, EDmv with HW, and CSA, suggesting that 
9.4T MRI is a useful tool for non-invasive monitoring and assessment of cardiac remodeling in mice models of 
LVH. One limitation of this study is that, since we did not perform echocardiography, we cannot confirm whether 
MRI is superior to echocardiography in assessing cardiac remodeling.
Generally, T1 mapping and late gadolinium enhancement imaging have been performed to detect myocardial 
fibrosis in CVDs and arrhythmia using MRI51–53. These imaging methods facilitate the visualization of myocardial 
extracellular volume, and several studies have verified that myocardial extracellular volume is moderately corre-
lated with collagen volume fraction54–57. However, T1 mapping and late gadolinium enhancement imaging must 
inject a contrast agent intravenously, and they are suitable for CVD with moderate or severe fibrosis.
In this study, in vivo real-time 9.4T MR imaging was able to accurately measure the changes in various LV 
parameters such as EDbv, ESbv, EDmv, EDmw, EF, and LVWT in mice model of Ang II-induced LVH with-
out contrast agent. Assessment of serial changes in LV function and overall remodeling time in a live animal is 
important for assessment of pathophysiology, as well as for testing efficacy of novel therapeutic agents. Therefore, 
real-time 9.4T MR imaging without contrast agents may be a useful tool for future cardiovascular research.
Moreover, real-time 9.4T MR imaging was also able to measure the AngII-induced LVH-attenuating effect 
of sRAGE for various LV parameters, with the comparison of delta values of the six parameters among groups 
(Fig. 4) being more obvious than that of the mean values (Fig. 3). This suggests that real-time 9.4T MR imaging 
may be a useful imaging tool for continuous assessment of the efficacy of treatment of therapeutic agents or drugs 
on LV function and remodeling in live animals.
Interestingly, statistically significant difference between AngII and AngII + sRAGE groups was only shown 
in myocardial-related factors without any changes in blood volume (Fig. 4c,d), with significant difference being 
demonstrated for EDmv and EDmw of AngII + sRAGE group compared to those of AngII group. This suggests 
that the efficacy of sRAGE in attenuating LVH induction by AngII was not dependent on changes in LV blood vol-
ume or blood pressure, but rather on the direct effect of sRAGE on cardiomyocyte hypertrophy. Although sRAGE 
showed LVH-attenuation effect, no reduction of blood pressure was detected after the treatment of sRAGE 
(Fig. 5a,b). Consistent with our results on blood pressure regulation of RAGE, Liliensiek et al. demonstrated that 
Figure 4. Graphs displaying the differential value of cardiac function and anatomy-indicating factors between 
before and after administration of AngII or sRAGE. (a) EDbv, (b) ESbv, (c) EDmv, (d) EDmw, (e) EF of LV, (f) 
LVWT. −/−: saline group, +/−: AngII group, −/+: sRAGE group, + /+, AngII + sRAGE group. Straight line: 
median value, dashed line: mean value, *p < 0.05, **p < 0.01, ***p < 0.0001.
7Scientific RepoRts |          (2019) 9:8475  | https://doi.org/10.1038/s41598-019-44933-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
arterial blood pressure was not affected by endothelial specific RAGE deletion or sRAGE treatment58. However, 
our previous study showed the anti-hypertrophic effect of sRAGE through inhibiting inflammation-mediated 
signaling pathways, such as ROS and NFκB in cardiomyocytes17. To support our results, blockade of ROS and 
NFκB-mediated inflammation has been implicated in cardiac pathogenesis59,60. In addition, the association 
between inflammatory markers, left ventricular hypertrophy, and diastolic dysfunction was also suggested in 
human study61.
A key finding from this study was that 1) we were able to accurately demonstrate AngII-induced LVH by 
9.4T MR imaging after 4-week administration of AngII, which was confirmed by gross histologic analysis. This 
result demonstrated that real-time 9.4T MR imaging may be useful for serial monitoring of changes in various 
Figure 5. Blood pressure and histological analysis after CINE-MRI. (a) Diastolic blood pressure, (b) systolic 
blood pressure, (c) harvested heart images, (d) heart weight/body weight, (e) microscopic images of WGA-
stained heart tissue, (f) CSA of myocardiocyte, *p < 0.01, **p < 0.05, ***p < 0.0001.
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parameters of LV function and remodeling such as EDbv, ESbv, EDmv, EDmw, EF, and LVWT in live animals; and 
that 2) the protective effect of sRAGE in attenuating AngII-induced LVH was demonstrated by 9.4T MR imaging 
and confirmed by gross histologic analysis, as well with their high correlativity. Since the efficacy of experimental 
drugs require assessment of changes in cardiac parameters from baseline to after intervention, accurate assess-
ment is limited by histologic assessment. The results from our study demonstrate that 9.4T MR imaging may be 
a useful tool to assess the efficacy of various experimental drugs on changes in cardiac function and remodeling 
between baseline and post intervention.
Conclusions
Cardiac function tracking using in vivo and real-time 9.4T MR imaging detected the cardiac remodeling induced 
by AngII, as well as the protective effect of sRAGE in attenuating AngII-induced LVH. Six parameters reflect-
ing cardiac function and anatomy were successfully measured, and showed statistically significant differences 
between AngII and AngII + sRAGE groups. AngII infusion for 4 weeks was sufficient to induce anatomical 
changes of the heart, although the magnitude of changes in LVWT and EF did not differ significantly between 
those seen in saline group and AngII + sRAGE group. When we compared AngII and AngII + sRAGE groups, 
decrease in ΔEDmv and ΔEDmw was observed by the administration of sRAGE with statistical significance. 
The results from our study demonstrate that 9.4T MR imaging may be a useful tool to non-invasively assess 
the efficacy of various interventions on changes in cardiac function and remodeling between baseline and 
post-intervention.
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